WOODCLIFF LAKE, N.J., Oct. 23 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that it's partner, Genpharm Inc. of Toronto, Canada, has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for pravastatin 10 mg, 20 mg, and 40 mg tablets. Pravastatin is the generic version of Bristol-Myers Squibb's Pravachol(R) and is used for treatment of certain hyperlipidemias. Par will begin shipping the product immediately.
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drug and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward- looking and are subject to risks and uncertainties, including the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against us, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission, such as the Company's Form 10-K, Form 10-Q, and Form 8-K reports.
Par Pharmaceutical Companies, Inc.CONTACT: Cecelia C. Heer of Par Pharmaceutical Companies, Inc.,+1-201-802-4000
Web site: http://www.parpharm.com//
